体外与体内证据表明从钙调神经磷酸酶抑制剂转换为mTOR抑制剂可能是EBV相关移植后淋巴增殖性疾病的一种免疫抑制策略
本研究从健康供者和肾移植患者中分离EBV抗原特异性T细胞和淋巴母细胞样细胞系,在标准免疫抑制剂存在或不存在下分析表型、T细胞受体库多样性和反应性。结果显示雷帕霉素和霉酚酸抑制淋巴母细胞样细胞系增殖,泼尼松龙和雷帕霉素处理T细胞细胞因子产生接近正常,他克莫司和环孢素A强烈抑制T细胞功能。作者认为基于mTOR抑制并减少或停用钙调神经磷酸酶抑制剂的方案可能是有前景的策略。
要点
- 雷帕霉素和霉酚酸抑制淋巴母细胞样细胞系增殖。
- 泼尼松龙和雷帕霉素处理T细胞细胞因子产生接近正常。
- 他克莫司和环孢素A强烈抑制T细胞功能包括杀伤活性。
核心结论
- 基于mTOR抑制并减少或停用钙调神经磷酸酶抑制剂的免疫抑制方案可能是EBV相关移植后淋巴增殖性疾病风险增加或已发病患者的有前景策略。
研究设计与样本
- 体外研究:从健康供者和肾移植患者中分离EBV抗原特异性T细胞和淋巴母细胞样细胞系,在标准免疫抑制剂他克莫司、环孢素A、泼尼松龙、雷帕霉素和霉酚酸存在或不存在下分析表型、T细胞受体库多样性和与自体淋巴母细胞样细胞系共培养时的T细胞反应性。
主要发现
- 雷帕霉素和霉酚酸抑制淋巴母细胞样细胞系增殖。
- 泼尼松龙和雷帕霉素处理T细胞显示接近正常的细胞因子产生。
- 霉酚酸降低T细胞增殖和活力,他克莫司和环孢素A强烈抑制T细胞功能包括杀伤活性。
临床怎么用
- 作者认为基于mTOR抑制并减少或停用钙调神经磷酸酶抑制剂的方案可能是EBV相关移植后淋巴增殖性疾病风险增加或已发病患者的有前景策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Post-transplant lymphoproliferative disorder is a life-threatening complication of immunosuppression following transplantation mediated by failure of T cells to control Epstein-Barr virus (EBV)-infected and transformed B cells. Typically, a modification or reduction of immunosuppression is recommended, but insufficiently defined thus far. In order to help delineate this, we characterized EBV-antigen-specific T cells and lymphoblastoid cell lines from healthy donors and in patients with a kidney transplant in the absence or presence of the standard immunosuppressants tacrolimus, cyclosporin A, prednisolone, rapamycin, and mycophenolic acid. Phenotypes of lymphoblastoid cell-lines and T cells, T cell-receptor-repertoire diversity, and T-cell reactivity upon co-culture with autologous lymphoblastoid cell lines were analyzed. Rapamycin and mycophenolic acid inhibited lymphoblastoid cell-line proliferation. T cells treated with prednisolone and rapamycin showed nearly normal cytokine production. Proliferation and the viability of T cells were decreased by mycophenolic acid, while tacrolimus and cyclosporin A were strong suppressors of T-cell function including their killing activity. Overall, our study provides a basis for the clinical decision for the modification and reduction of immunosuppression and adds information to the complex balance of maintaining anti-viral immunity while preventing acute rejection. Thus, an immunosuppressive regime based on mTOR inhibition and reduced or withdrawn calcineurin inhibitors could be a promising strategy for patients with increased risk of or manifested EBV-associated post-transplant lymphoproliferative disorder.
引用
- Thieme CJ, Schulz M, Wehler P, et al. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder. Kidney Int. 2022. PMID: 36103953. doi:10.1016/j.kint.2022.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。